REG - Oxford Biomedica PLC - Block Listing Application

Oxford BioMedicaAnnouncement

31/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240131:nRSe4253Ba&default-theme=true

RNS Number : 4253B  Oxford Biomedica PLC  31 January 2024

 

 

 

Oxford Biomedica

Block Listing Application

 

Oxford, UK - 31 January 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Company"), a quality and innovation-led cell and gene
therapy CDMO, today announces that  application has been made to the
Financial Conduct Authority and the London Stock Exchange for admission to (i)
the Premium segment of the Official List and (ii) to trading on the London
Stock Exchange for a block listing of 300,000 ordinary shares of 50 pence each
(the "Ordinary Shares").

 

The Ordinary Shares are being reserved under a block listing and will be
issued from time to time pursuant to the following schemes:

 

·      OXB Long Term Incentive Plan (LTIP) (250,000 Ordinary Shares);

·      OXB Deferred Bonus Plan (DBP) (50,000 Ordinary Shares);

 

It is expected that admission to the Official List and the London Stock
Exchange of the New Ordinary Shares will become effective on 5(th) February
2024. The New Ordinary Shares will rank pari passu in all respects with the
Group's existing ordinary shares in issue.

 

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene
therapy CDMO with a mission to enable its clients to deliver life changing
therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV), adenoviral vectors, and other viral vector types. Oxford
Biomedica's world-class capabilities span from early-stage development to
commercialisation. These capabilities are supported by robust
quality-assurance systems, analytical methods and depth of regulatory
expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has locations across Oxfordshire, UK, Lyon and Strasbourg, France, and near
Boston, MA, US. Learn more at www.oxb.com (https://www.oxb.com/) , and follow
us on LinkedIn (https://www.linkedin.com/company/oxford-biomedica/) and
YouTube (https://www.youtube.com/user/OxfordBioMedica) .

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALSBRGDBLGXDGSG